Dosage and administration regimen for treating or preventing green-barre syndrome by using anti-C5 antibody kovar monoclonal antibody

Through the load and maintenance dose regimen of anti-C5 antibody covarizumab, combined with IVIg, the shortcomings of existing GBS treatment in long-term recovery and prognosis were solved, effective inhibition of the complement system was achieved, and the patient's motor function was improved. Neuroprotection promotes long-term recovery.

CN118974082APending Publication Date: 2024-11-15F HOFFMANN LA ROCHE & CO AG +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031438.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-04
Filing Date
2023-04-03
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing treatments for Guillin-Barre syndrome (GBS) such as intravenous immunoglobulin (IVIg) and plasma replacement are effective in the acute phase, but there is a lack of evidence for long-term recovery and prognosis, and it is unclear whether it can improve patients. Long-term outcomes, complement activation is considered to play an important role in the pathogenesis of GBS, but existing complement inhibitors such as ecucizumab have limited effect in clinical trials.

Method used

After using anti-C5 antibody covarizumab, 1500mg of loading dose was administered intravenously, 340mg of maintenance dose was then administered subcutaneously, combined with standard care intravenous injection of immunoglobulin (IVIg) to inhibit the complement system and prolong the antibody half-life. Improve the therapeutic effect.

Benefits of technology

Through this scheme, complement activation can be effectively inhibited, motor function can be improved, and long-term neuroprotection can be provided, ensuring nerve regeneration and germination of the lateral collaterals after the acute phase of GBS, thereby promoting long-term recovery of patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005064524660000201
    Figure BDA0005064524660000201
  • Figure BDA0005064524660000221
    Figure BDA0005064524660000221
  • Figure BDA0005064524660000231
    Figure BDA0005064524660000231
Patent Text Reader

Abstract

The present invention relates to doses and administration regimens of anti-C5 antibodies, in particular anti-C5 antibody kovar monoclonal antibodies, for use in a method of treating or preventing GBS in a subject. The doses and treatment regimens of the invention comprise administering to the subject an anti-C5 antibody, preferably said anti-C5 antibody kovar monoclonal antibody, in a load dose followed by administering one or more sustaining doses of said anti-C5 antibody wherein the initial administration of the load dose is intravenously administered to the subject, and wherein the sustaining dose of said one or more sustaining doses of said anti-C5 antibody, preferably said one or more sustaining doses of said one or more sustaining doses are administered to the subject. And the sustaining dose is administered subcutaneously at a dose lower than the intravenous administration load dose.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to anti-C5 antibodies, in particular, anti-C5 antibody kovalimab for use in a method for treating or preventing Guillain-Barré syndrome (GBS) in a dosage and administration regimen. The dosage and treatment regimen of the present invention comprises administering an anti-C5 antibody, preferably an anti-C5 antibody kovalimab, to a subject in a loading dose, followed by one or more maintenance doses of the anti-C5 antibody, wherein the initial loading dose is administered intravenously to the subject, and the dose is administered subcutaneously at a dose lower than the intravenous loading dose. Background Art

[0002] The canonical pathway is typically activated by the formation of an antigen-antibody complex. Independently, the first step in activating the lectin pathway is binding to specific lectins, such as mannan binding lectin (MBL), H-ficolin, M-ficolin, L-ficolin, and the C-type lectin CL-11. In contrast, the alternative pathway spontaneously undergoes low-level turnover activation that can be easily amplified on foreign or other abnormal surfaces (bacteria, yeast, virus-infected cells, or damaged tissue). These pathways converge at the point where complement component C3 is cleaved by active proteases to produce C3a and C3b.

[0003] Guillain-Barré syndrome (GBS) is a rare but potentially fatal disease of the peripheral nerves and nerve roots that is usually triggered by infection. GBS is an acute, heterogeneous, paralytic, inflammatory peripheral neuropathy characterized by rapidly progressive, symmetrical limb weakness that leads to diminished or even absent muscle response to stimulation [1].

[0004] The prognosis of GBS is determined by the extent of axonal loss during the acute phase, and if axonal damage is minimized by effective early treatment during the acute phase, sufficient neurogenesis and collateral sprouting from surviving motor axons can be expected to result in long-term recovery several months after the peak of the disease. Intravenous immunoglobulin (IVIg) (400 mg / kg body weight per day for 5 days) and plasma exchange (PE) (50 mL plasma / kg body weight five times over 1-2 weeks), both introduced in the 1980s, are established treatments for GBS and are considered equally effective as first-line therapies. PE and IVIg have been shown to accelerate recovery during the acute and subacute phases of the disease beginning within 2 weeks of the onset of weakness [2,3,4]. Outside of these time periods, evidence of efficacy is lacking, and it is unclear whether these treatments are sufficient to improve long-term outcomes in patients with Guillain-Barré syndrome [3,4]. Because IVIg is easier to administer and is generally more widely available than plasma exchange, it is often the treatment of choice. Inhibition of complement is a novel approach for the treatment of GBS; complement activation appears to drive neurodegeneration in GBS. Early acute treatment may prevent complement-mediated long-term neurological damage. Complement activation is thought to play an important role in the pathogenesis of all GBS variants [5]. Human proof-of-concept data supporting the use of a C5 complement inhibitor (eculizumab) are available from the Phase 2 JET study in patients with severe GBS [6]. This study was a 24-week, multicenter, double-blind, placebo-controlled, randomized Phase 2 trial conducted in Japan. In this study, the primary outcome, the proportion of patients who regained the ability to walk by week 4, did not exceed the pre-specified response threshold (50%) in the eculizumab group. However, eculizumab showed potential evidence of improved motor function in secondary endpoints [6]. Kovalizumab is a novel humanized anti-C5 monoclonal antibody[7] that binds to complement protein C5 with high affinity, thereby inhibiting its cleavage into C5a and C5b and preventing the formation of the terminal complement complex C5b-9 (MAC). Kovalizumab has been shown[8] to inhibit terminal complement-mediated intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH).

[0005] Kovalizumab is based on SMART-Ig (Recycling Antibody TM ) technology [7]. It provides effective target processing and enhanced neonatal crystallizable fragment receptor (FcRn) binding, improving antibody recycling efficiency, thereby leading to half-life extension and complement inhibition. In addition, the physicochemical properties of kovalizumab support the development of high-concentration formulations. The combination of SMART-Ig and highly concentrated formulations enables SC administration once every 4 weeks (Q4W).

[0006] The half-lives of IVIg and kovalizumab depend on recycling through the FcRn receptor in endosomes, and considering the competition of both molecules for binding to the FcRn receptor, the effect of co-administration of IVIg on the PK of kovalizumab for maintaining C5 inhibition over a 28-day period was investigated. Summary of the invention

[0007] The present invention solves this need by providing embodiments as defined in the claims.

[0008] The present invention relates to an anti-C5 antibody for use in a method for treating or preventing GBS in a subject, wherein the method comprises the following consecutive steps:

[0009] (a) administering a 1500 mg loading dose of anti-C5 antibody once intravenously to the subject,

[0010] (b) subsequently administering to the subject subcutaneously at least one maintenance dose of 340 mg of the anti-C5 antibody.

[0011] In the context of the present invention, the subject to be treated is preferably a patient having a body weight higher than 100 kg.In the context of the present invention, the subject to be treated is a subject suffering from GBS.

[0012] In addition, the present invention relates to the use of anti-C5 antibodies for the treatment or prevention of GBS. In the context of the present invention, the present invention relates to the treatment or prevention of GBS in patients treated with a combination of an anti-C5 antibody (preferably kovalizumab) and standard of care (SOC) intravenous immunoglobulin (IVIg). IVIg is a pool of immunoglobulins prepared by separating immunoglobulins from other components of plasma from healthy donor plasma. Examples of IVIg are Asceniv, Bivigam, Carimune, Cutaquig, Cuvitru, Flebogamma, Gammagard, GamaSTAN, Gammaked, Gammaplex, Gamunex-C, Hizentra, Hyqvia, Octagam, Panzyga, Privigen, Xembify. Therefore, the dosage and administration regimen of the anti-C5 antibodies described herein, in particular the anti-C5 antibody kovalizumab, are administered to patients treated with a combination of anti-C5 antibodies, preferably kovalizumab and IVIg.

[0013] Therefore, the present invention relates to an anti-C5 antibody, preferably the anti-C5 antibody kovalimab, for use in a method for treating or preventing GBS in a subject, preferably a subject weighing more than 100 kg, wherein the method comprises the following consecutive steps:

[0014] (a) administering a 1500 mg loading dose of anti-C5 antibody once intravenously to the subject,

[0015] (b) subsequently administering to the subject subcutaneously at least one 340 mg loading dose of the anti-C5 antibody.

[0016] "Loading dose" refers to the dose of anti-C5 antibody administered to a subject with GBS at the beginning of treatment, i.e., at the beginning of a treatment regimen. In pharmacokinetics (PK), a "loading dose" is an initial higher dose of a drug that can be given to a patient at the beginning of a treatment course, which is then reduced to a lower dose. In the context of the present invention, the loading dose is first administered to the subject to be treated by intravenous administration. In the context of the present invention, the loading dose is administered once in a dose of 1500 mg. Therefore, in the context of the present invention, a loading dose of a composition formulated for intravenous administration is administered intravenously to a subject once prior to subcutaneous administration of one or more doses of a pharmaceutical composition formulated for subcutaneous administration.

[0017] According to the present invention, the initial dose is followed by subsequent doses of an equal or lesser amount of anti-C5 antibody, spaced closely enough to maintain the concentration of the anti-C5 antibody at or above an effective target level. Thus, in the context of the present invention, one or more maintenance doses are administered to the patient after the loading dose. "Maintenance dose" refers to a dose of anti-C5 antibody administered to a subject with a C5-related disease to maintain the concentration of the anti-C5 antibody above a certain effective threshold of the anti-C5 antibody concentration during the treatment period. In the context of the present invention, the target level of anti-C5 antibody is a median of about 100 μg / ml or more during the treatment period. The target level of anti-C5 concentration within the present invention can be determined in a biological sample of the subject to be treated. The means and methods for determining the anti-C5 concentration in a biological sample are within the common sense of the technician and can be determined, for example, by immunoassay. Preferably, in the context of the present invention, the immunoassay is ELISA. Preferably, one or more maintenance doses are administered subcutaneously to the patient at one or more doses of 340 mg of anti-C5 antibody. Therefore, in the context of the present invention, at least one maintenance dose or more maintenance doses are administered to the subject, wherein one or more maintenance doses are administered subcutaneously at a dose of 340 mg. In the context of the present invention, after intravenous administration of a 1500 mg loading dose of anti-C5 antibody, at least one 340 mg maintenance dose of anti-C5 antibody is administered to the patient. The subcutaneous administration of one or more doses is administered subcutaneously to the subject at least once at a dose of 340 mg of anti-C5 antibody 1 day to 3 weeks (21 days) after the start of intravenous administration of anti-C5 antibody. Therefore, in the context of the present invention, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 days after the start of intravenous administration of anti-C5 antibody, a 340 mg dose of anti-C5 antibody is administered subcutaneously to the subject at least once. Preferably, 1 day after the start of intravenous administration of anti-C5 antibody, a 340 mg dose of anti-C5 antibody is administered to the subject. More preferably, a 340 mg dose of anti-C5 antibody is administered subcutaneously one day after the start of intravenous administration. In the context of the present invention, at least one additional dose of 340 mg of anti-C5 antibody is administered subcutaneously to the subject 1 week (7 days), 2 weeks (14 days) or 3 weeks (21 days) after the start of intravenous administration of anti-C5 antibody. Most preferably, an additional dose of 340 mg of anti-C5 antibody is administered subcutaneously 1 week (7 days), 2 weeks (14 days) and 3 weeks (21 days) after the start of intravenous administration of anti-C5 antibody. Therefore, in the context of the present invention, 1, 2, 3, 4 and / or 5 doses are administered to the subject, wherein the loading dose is administered intravenously to the subject at a dose of 1500 mg, and wherein 1, 2, 3 or 4 doses are administered subcutaneously to the patient at a dose of 340 mg.In the context of the present invention, 4 loading doses are preferably administered subcutaneously, each of which has a dose of 340 mg of the anti-C5 antibody, wherein an additional dose is administered subcutaneously once 1 day after the start of intravenous administration of the anti-C5 antibody, followed by a maintenance dose administered subcutaneously once a week 1 week, 2 weeks and 3 weeks after the start of intravenous administration of the anti-C5 antibody. For example, the total amount of anti-C5 antibody administered via one or more maintenance doses is 2860 mg, and the one or more maintenance doses correspond to intravenous administration of 1500 mg (day 1), followed by subcutaneous administration of 340 mg (day 2), 340 mg (day 8), 340 mg (day 15) and 340 mg (day 22).

[0018] In particular, the present invention relates to an anti-C5 antibody for use in a method for treating or preventing a C5-related disease in a subject, preferably a subject weighing more than 100 kg, wherein the method comprises the following consecutive steps:

[0019] (i) administering a 1500 mg loading dose of anti-C5 antibody once intravenously to the subject;

[0020] (ii) one day after starting intravenous administration of the anti-C5 antibody, subcutaneously administering a maintenance dose of 340 mg of the anti-C5 antibody to the subject;

[0021] (iii) administering a maintenance dose of 340 mg of the anti-C5 antibody subcutaneously to the subject once a week 1 week (7 days), 2 weeks (14 days), and 3 weeks (21 days) after the start of intravenous administration of the anti-C5 antibody.

[0023] The term "intravenous administration" / "intravenously administering" in the context of the present invention refers to the administration of the anti-C5 antibody into the vein of a subject so that the body of the patient to be treated accepts the anti-C5 antibody in about 15 minutes or less, preferably 5 minutes or less. For intravenous administration, the anti-C5 antibody must be formulated so that it can be administered via a suitable device, such as (but not limited to) a syringe. In the context of the present invention, formulations for intravenous administration contain 50 to 350 mg of anti-C5 antibody, 1 to 100 mM buffer, such as histidine / aspartic acid at a pH of 5.5±1.0, 1 to 100 mM amino acids (such as arginine) and 0.01% to 0.1% non-ionic surfactant (such as poloxamer). Preferably, in the context of the present invention, the formulation for intravenous administration is provided in a 2 mL glass vial containing: 170 mg / ml kovalizumab, 30 mM histidine / aspartic acid (pH 5.8), 100 mM arginine hydrochloride and 0.05% poloxamer 188 TM The formulation is then administered to the patient within a tolerated time period, such as 5 minutes, 15 minutes, 30 minutes, 90 minutes or less. In addition, formulations for intravenous administration are administered to the patient to be treated in an injection volume of between 1 ml and 15 ml, preferably about 6 ml.

[0024] The term "subcutaneous administration" / "subcutaneously administering" in the context of the present invention refers to the introduction of the anti-C5 antibody into the subcutaneous tissue of an animal or human patient, preferably into a pocket between the skin and the underlying tissue, by relatively slow, continuous delivery from a drug container. The pocket can be created by pinching or pulling the skin up and away from the underlying tissue. For subcutaneous administration, the anti-C5 antibody must be formulated so that it can be administered via a suitable device, such as (but not limited to) a syringe, a prefilled syringe, an injection device, an infusion pump, an injection pen, a needle-free device, or via a subcutaneous patch delivery system. In the context of the present invention, formulations for subcutaneous administration contain 50 to 350 mg of the anti-C5 antibody, 1 to 100 mM of a buffer, such as histidine / aspartic acid at a pH of 5.5±1.0, 1 to 100 mM of an amino acid (such as arginine), and 0.01% to 0.1% of a non-ionic surfactant (such as a poloxamer). Preferably, in the context of the present invention, the formulation for intravenous administration is provided in a 2.25 pre-filled syringe containing: 170 mg / ml kovalizumab, 30 mM histidine / aspartic acid (pH 5.8), 100 mM arginine hydrochloride and 0.05% poloxamer 188 TM . In the context of the present invention, the formulation for subcutaneous administration is provided in a prefilled syringe with a needle safety device. The injection device for subcutaneous administration contains about 1 to 15 ml or more, preferably 2.25 ml of a formulation containing an anti-C5 antibody for subcutaneous administration. Under normal circumstances, the injection volume for subcutaneous administration is 1 to 15 ml, preferably 2 ml (340 mg of kovalizumab) or 4 ml (680 mg of kovalizumab). In the context of the present invention, subcutaneous administration refers to the introduction of anti-C5 antibodies into the subcutaneous tissue of a patient to be treated by relatively slow and continuous delivery from a drug container for a period of time, including but not limited to 30 minutes or less, 90 minutes or less. Optionally, administration can be performed by subcutaneous implantation of a drug delivery pump implanted under the skin of the patient to be treated, wherein the pump delivers a predetermined amount of anti-C5 antibodies for a predetermined period of time, such as 30 minutes, 90 minutes, or a period of time spanning the duration of the treatment regimen.

[0025] In the context of the present invention, the above dosages and treatment regimens can be used to treat or prevent GBS in subjects co-administered with IVIg. For example, the treatment regimens of the present invention can be used to treat patients with GBS, wherein the patients also receive standard care. Preferably, SOC is intravenous administration of IVIg.

[0026] The present invention also relates to a pharmaceutical composition for use in combination with IVIg for the treatment or prevention of GBS, the composition comprising an anti-C5 antibody, preferably kovalimab, and administered by the following administration steps:

[0027] (a) administering a 1500 mg loading dose of the anti-C5 antibody once intravenously to the subject; and

[0028] (b) subcutaneously administering to the subject at least one 340 mg maintenance dose of the anti-C5 antibody.

[0029] In one embodiment, wherein

[0030] (i) administering 1500 mg of anti-C5 antibody (loading dose) once intravenously to the subject;

[0031] (ii) One day after the start of intravenous administration of the anti-C5 antibody, 340 mg of the anti-C5 antibody was subcutaneously administered to the subject (maintenance dose).

[0032] In a further embodiment, the pharmaceutical composition comprising IVIg is administered by the following steps:

[0033] (a) on the same day as the loading dose of C5 antibody, 400 mg / kg of IVIg was administered intravenously to the subject once;

[0034] (b) 400 mg / kg of IVIg was intravenously administered to the subject every day 1 day, 2 days, 3 days, and 4 days after the start of intravenous administration of the anti-C5 antibody.

[0035] The present invention also relates to a pharmaceutical composition for treating or preventing GBS in combination with an anti-C5 antibody (preferably kovalimab), the composition comprising IVIg and administered by the following administration steps:

[0036] (a) On the same day as the loading dose (1500 mg) of C5 antibody, subjects were intravenously administered once

[0037] (b) administering intravenously to a subject every day 1 day, 2 days, 3 days, and 4 days after the start of intravenous administration of the anti-C5 antibody.

[0038] In one embodiment, the intravenous administration dose of IVIg in a) is 400 mg / kg. In a further embodiment, the intravenous administration dose of IVIg (step b) is

[0039] 400 mg / kg per day on days 2, 3 and 4 after starting intravenous administration of anti-C5 antibody.

[0040] In a further embodiment, the pharmaceutical composition comprising an anti-C5 antibody is administered by the following steps:

[0041] (i) administering 1500 mg of anti-C5 antibody (loading dose) once intravenously to the subject;

[0042] (ii) One day after the start of intravenous administration of the anti-C5 antibody, 340 mg of the anti-C5 antibody was subcutaneously administered to the subject (maintenance dose).

[0043] In particular, the present invention relates to a pharmaceutical composition comprising an anti-C5 antibody for use in a method of treating or preventing GBS in a subject, preferably a subject weighing more than 100 kg, wherein the method comprises the following steps:

[0044] (i) administering a 1500 mg loading dose of anti-C5 antibody once intravenously to the subject;

[0045] (ii) one day after starting intravenous administration of the anti-C5 antibody, subcutaneously administering a maintenance dose of 340 mg of the anti-C5 antibody to the subject;

[0046] (iii) administering to the subject subcutaneously a maintenance dose of 340 mg of the anti-C5 antibody once a week 1 week (7 days), 2 weeks (14 days), and 3 weeks (21 days) after the start of intravenous administration of the anti-C5 antibody;

[0047] Wherein anti-C5 antibody is used in combination with IVIg,

[0048] (a) On the same day as the loading dose of the C5 antibody of (i), 400 mg / kg of IVIg was intravenously administered once to the subject.

[0049] (b) 400 mg / kg of IVIg was intravenously administered to the subject every day 1 day, 2 days, 3 days, and 4 days after the start of intravenous administration of the anti-C5 antibody.

[0050] The administration of the initial dose of anti-C5 antibody and IVIg can be administered together or separately. If the anti-C5 antibody and IVIg are administered separately, they can be administered directly in sequence, or they can be administered at time intervals. For example, a loading dose of anti-C5 antibody is first administered, followed by a loading dose of IVIg, or a loading dose of IVIg can be administered first, followed by a loading dose of anti-C5 antibody. Alternatively, two loading doses can be administered at time intervals, for example, two loading doses can be separated by 5, 10, 15, 20, 30, 40, 50, 60 minutes; up to 2, 3, 4, 5, 6, 7, 8, 9, 10 hours, or 1 to 23 hours, 1 to 16 hours, 1 to 8 hours, 1 to 4 hours, 1 to 2 hours. For example, a loading dose of anti-C5 antibody is administered in the morning, and the first dose of IVIg is administered in the evening, or the first dose of IVIg is administered in the morning, and the loading dose of anti-C5 antibody is administered in the evening.

[0051] The present invention also relates to a combination of an anti-C5 antibody and IVIg for use in a method for treating or preventing GBS in a subject, preferably a subject weighing more than 100 kg, wherein the method comprises the following consecutive steps:

[0052] (i) administering to the subject a loading dose of 1500 mg of the anti-C5 antibody once intravenously and administering 400 mg / kg of IVIg once intravenously on the same day;

[0053] (ii) one day after starting intravenous administration of the anti-C5 antibody, administering to the subject subcutaneously a maintenance dose of 340 mg of the anti-C5 antibody and administering 400 mg / kg of IVIg intravenously on the same day;

[0054] (iii) 400 mg / kg of IVIg was intravenously administered daily on days 2, 3, and 4 after the start of intravenous administration of the anti-C5 antibody.

[0055] (IV) 1 week (7 days), 2 weeks (14 days), and 3 weeks (21 days) after the start of intravenous administration of the anti-C5 antibody, a maintenance dose of 340 mg of the anti-C5 antibody is subcutaneously administered to the subject once a week.

[0056] The administration of the initial dose of anti-C5 antibody and IVIg can be administered together or separately. If the anti-C5 antibody and IVIg are administered separately, they can be administered directly in sequence, or they can be administered at time intervals. For example, a loading dose of anti-C5 antibody is first administered, followed by a loading dose of IVIg, or a loading dose of IVIg can be administered first, followed by a loading dose of anti-C5 antibody. Alternatively, two loading doses can be administered at time intervals, for example, two loading doses can be separated by 5, 10, 15, 20, 30, 40, 50, 60 minutes; up to 2, 3, 4, 5, 6, 7, 8, 9, 10 hours, or 1 to 23 hours, 1 to 16 hours, 1 to 8 hours, 1 to 4 hours, 1 to 2 hours. For example, a loading dose of anti-C5 antibody is administered in the morning, and the first dose of IVIg is administered in the evening, or the first dose of IVIg is administered in the morning, and the loading dose of anti-C5 antibody is administered in the evening.

[0057] In the context of the present invention, a "week" refers to a period of 7 days.

[0058] In the context of the present invention, "month" refers to a period of 4 weeks.

[0059] "Treatment" in the context of the present invention includes "induction therapy" and at least "maintenance therapy" in sequence. Typically, treatment according to the present invention includes "induction therapy" and at least one "maintenance therapy". Typically, treatment according to the present invention may be 3 weeks to 1 month, for example 28 days.

[0060] "Induction therapy" comprises administering a loading dose of anti-C5 antibody to the subject intravenously, preferably a dose of 1500 mg. As explained above, "maintenance therapy" comprises sequentially consecutive (i) maintenance periods, in which one or more maintenance doses are administered to the subject subcutaneously. In the context of the present invention, preferably a maintenance dose of 340 mg of anti-C5 antibody is administered to the subject 1 day, 1 week (7 days), 2 weeks (14 days) and 3 weeks (21 days) after the loading dose administered intravenously is administered to the subject. Preferably, the loading dose administered intravenously has a dose of 1500 mg. The maintenance dose administered subcutaneously to the subject to be treated has a dose of 1360 mg. Therefore, in the context of the present invention, a dose of 2360 mg of anti-C5 antibody is administered intravenously or subcutaneously to the subject to be treated during the treatment period.

[0061] In the context of the present invention, the anti-C5 antibody is preferably kovalimab. The sequence details of the anti-C5 antibody kovalimab (CAS number: 1917321-26-6) are disclosed in the proposed International Nonproprietary Drug Name (INN) List No. 119 as published in WHO Drug Information (2018), Volume 32, Issue 2, pages 302 and 303. The sequence of the anti-C5 antibody kovalimab is also shown in SEQ ID NO: 1 (heavy chain) and SEQ ID NO: 2 (light chain). The generation of the anti-C5 antibody kovalimab used in the present invention is described in WO 2016 / 098356 (for details, see Example 1.1). In addition, in the context of the present invention, the anti-C5 antibody kovalimab is administered to the patient by a preparation for intravenous administration or for subcutaneous administration. Preferably, in the context of the present invention, the dose provided herein is administered intravenously or subcutaneously as one or more fixed doses.

[0062] The formulation for intravenous administration comprises 50 to 350 mg of the anti-C5 antibody kovalizumab, 1 to 100 mM of a buffer such as histidine / aspartic acid at pH 5.5 ± 1.0, 1 to 100 mM of an amino acid such as arginine, and 0.01% to 0.1% of a non-ionic surfactant such as poloxamer. Preferably, in the context of the present invention, the formulation for intravenous administration is provided in a 2 mL glass vial containing the following ingredients: 170 mg / ml kovalizumab, 30 mM histidine / aspartic acid (pH 5.8), 100 mM arginine hydrochloride, and 0.05% poloxamer 188 TM .

[0063] The formulation for subcutaneous administration comprises 50 to 350 mg of the anti-C5 antibody kovalizumab, 1 to 100 mM of a buffer such as histidine / aspartic acid at pH 5.5 ± 1.0, 1 to 100 mM of an amino acid such as arginine, and 0.01% to 0.1% of a non-ionic surfactant such as poloxamer. Preferably, in the context of the present invention, the formulation for intravenous administration is provided in a 2.25 pre-filled syringe containing the following ingredients: 170 mg / ml kovalizumab, 30 mM histidine / aspartic acid (pH 5.8), 100 mM arginine hydrochloride, and 0.05% poloxamer 188 TM .

[0064] The patient described in the context of the present invention is a patient suffering from GBS. Preferably, the patient in the context of the present invention is a patient with a body weight of more than 100 kg. In the context of the present invention, the patient is preferably co-administered with IVIg.

[0065] Preferably, IVIg is administered in combination with an anti-C5 antibody to a subject suffering from GBS, wherein 400 mg / kg of IVIg

[0066] (a) On the same day as the loading dose (1500 mg) of C5 antibody, subjects were intravenously administered once

[0067] (b) administering intravenously to the subject every day 1 day, 2 days, 3 days and 4 days after the start of intravenous administration of the anti-C5 antibody

[0068] Furthermore, the present invention relates to a method for treating or preventing a C5-related disease in a subject, wherein the method comprises the following consecutive steps:

[0069] (a) administering a 1500 mg loading dose of the anti-C5 antibody once intravenously to the subject; and

[0070] (b) subcutaneously administering to the subject at least one 340 mg maintenance dose of the anti-C5 antibody.

[0071] Preferably in the context of the present invention, the method of treating or preventing a C5-related disease in a subject is performed by the following administration steps:

[0072] (i) administering a 1500 mg loading dose of anti-C5 antibody once intravenously to the subject;

[0073] (ii) one day after starting intravenous administration of the anti-C5 antibody, subcutaneously administering a maintenance dose of 340 mg of the anti-C5 antibody to the subject;

[0074] (iii) administering a loading dose of 340 mg of the anti-C5 antibody subcutaneously to the subject once a week 1, 2, and 3 weeks after the start of intravenous administration of the anti-C5 antibody.

[0075] Even more preferably in the context of the present invention, the method of treating or preventing a C5-related disease in a subject is performed by the following administering step:

[0076] (i) administering to the subject a loading dose of 1500 mg of the anti-C5 antibody once intravenously and administering 400 mg / kg of IVIg once intravenously on the same day;

[0077] (ii) one day after starting intravenous administration of the anti-C5 antibody, administering to the subject subcutaneously a maintenance dose of 340 mg of the anti-C5 antibody and administering 400 mg / kg of IVIg intravenously on the same day;

[0078] (iii) 400 mg / kg of IVIg was intravenously administered daily on days 2, 3, and 4 after the start of intravenous administration of the anti-C5 antibody.

[0079] (IV) 1 week (7 days), 2 weeks (14 days), and 3 weeks (21 days) after the start of intravenous administration of the anti-C5 antibody, a maintenance dose of 340 mg of the anti-C5 antibody is subcutaneously administered to the subject once a week.

[0080] As explained above, it is preferred in the context of the present invention that the anti-C5 antibody used in the context of the dosage and administration regimen is kovalizumab. Furthermore, the definitions given above also apply to the above methods of treating or preventing C5-related diseases. It is also preferred in the context of the present invention that the subject to be treated has a body weight higher than 100 kg. BRIEF DESCRIPTION OF THE DRAWINGS

[0081] The accompanying drawings show:

[0082] Figure 1 Pharmacokinetics of radiolabeled IVIg and the proportion of total radioactivity in serum as a percentage of the injected dose

[0083] Figure 2 A Taken from Kendrick F, Evans ND, Berlanga O, Harding SJ, ChappellMJ. Parameter identification for a model of neonatal Fc receptor-mediatedrecycling of endogenous immunoglobulin G in humans. Front Immunol. 10. (2019)

[0084] Figure 2 Mean (SEM) M281 PK profiles at five different single ascending doses in a first-in-human study in healthy volunteers

[0085] Image extracted from Momenta R&D Day 2018 Presentation

[0086] Figure 3 Mean serum IgG concentrations as a percentage (%) of baseline with M281 dose in the single ascending dose (SAD) (A) and multiple ascending dose (MAD) (B) studies

[0087] Figure extracted from Ling LE, Hillson JL, Tiessen RG et al. M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgGReduction in a First-in-Human Study. Clin Pharmacol Ther. (2018)

[0088] Figure 4 PK / PD model of kovalimab, C5, IgG, and M281 in serum and their recycling in endosomes via FcRn

[0089] Each box corresponds to the concentration (nM) of an entity defined in Table 4. [Ab1], [Ab1Ag], [AgAb1Ag], [Ag], [IgG], [IgG*], [M281] are the concentrations in the central compartment. [Ab1]p, [Ab1Ag]p, [AgAb1Ag]p are the concentrations in the peripheral compartment. CLAb1 and CLAg are the clearance rates of free Ab1 and free Ag (L / day / kg). CLe,Ab1, CLe,Ab1Ag, CLe,AgAb1Ag, CLe,IgG, CLe,M281 are the clearance rates of Ab1, Ab1Ag, AgAb1Ag, IgG, and M281 into endosomes (L / day / kg). CLe,Ab1 recy, CLe,IgG recy, CLe,M281 recy are the clearance rates of Ab1, IgG, and M281 from endosomes back to plasma (L / day / kg). Ab1, IgG and M281 that are not bound to FcRn are eliminated at a rate defined by the elimination constants ke,Ab1, ke, IgG and ke, M281 (1 / day). Vc, Vc IgG and Vc M281 are the central compartment volumes (L / kg) of Ab1 / Ag, IgG and M281. VpAb1, Vp Ab1Ag, Vp AgAb1Ag and Vp IgG are the peripheral compartment volumes (L / kg). Q Ab1 and Q IgG are the intercompartmental clearance rates (L / day / kg). kinAg is the productivity of Ag (nmol / day). konAb1 (nM / day) and koffAb1 (1 / day) are the association and dissociation rates of Ab1 and Ag.

[0090] Figure 5 ODE equation of the binding model of Ab1 and Ag in serum

[0091] Figure 6 ODE equations for IgG, IgG* and M281 in serum

[0092] Figure 7 ODE equations for Ab1, IgG, IgG*, and M281 in endosomes

[0093] Figure 8 Ab1 disposal from serum to endosomes and Ab1 recycling from endosomes to serum Fig. 9 Equation for Ab1 in endosomes

[0094] Fig.10 Individual goodness of fit of the model for total Ab1, total Ag and free Ag in COMPOSER Part 1 (healthy volunteer subjects 11001-11007)

[0095] Each row corresponds to a subject, and the columns correspond to total Abl (also called [Abl] total = [Abl] + [AblAg] + [AgAb1Ag]), total Ag (also called [Ag] total = [Ag] + [Ab1Ag] + 2 [AgAb1Ag]), and free Ag (also called [Ag]). The observed concentrations in the COMPOSER study (Example 2.1) are shown in black dots, and the solid lines are simulation results using the empirical Bayes model parameter estimates for each subject.

[0096] Fig.11 Individual goodness of fit of the model for total Ab1, total Ag and free Ag in COMPOSER Part 1 (healthy volunteer subjects 11008-11015)

[0097] Each row corresponds to a subject, and the columns correspond to total Ab1 (also called [Ab1] total = [Ab1] + [Ab1Ag] + [AgAb1Ag]), total Ag (also called [Ag] total = [Ag] + [Ab1Ag] + 2 [AgAb1Ag]), and free Ag (also called [Ag]). The observed concentrations in the COMPOSER study (Example 2.1) are shown as black dots, and the solid lines are simulation results using the empirical Bayes model parameter estimates for each subject.

[0098] Fig.12 Individual goodness-of-fit of models for total Ab1, total Ag, and free Ag in COMPOSER Part 2 (untreated PNH patients)

[0099] Each row corresponds to a subject, and the columns correspond to total Abl (also called [Abl] total = [Abl] + [AblAg] + [AgAb1Ag]), total Ag (also called [Ag] total = [Ag] + [Ab1Ag] + 2 [AgAb1Ag]), and free Ag (also called [Ag]). The observed concentrations in the COMPOSER study (Example 2.1) are shown in black dots, and the solid lines are simulation results using the empirical Bayes model parameter estimates for each subject.

[0100] Fig.13 Individual goodness-of-fit of models for total Ab1, total Ag, and free Ag in COMPOSER Part 4 (untreated PNH patients)

[0101] Each row corresponds to a subject, and the columns correspond to total Abl (also called [Abl] total = [Abl] + [AblAg] + [AgAb1Ag]), total Ag (also called [Ag] total = [Ag] + [Ab1Ag] + 2 [AgAb1Ag]), and free Ag (also called [Ag]). The observed concentrations in the COMPOSER study (Example 2.1) are shown in black dots, and the solid lines are simulation results using the empirical Bayes model parameter estimates for each subject.

[0102] Fig.14 Model individual goodness of fit for radiolabeled IgG* in serum (top) and whole-body radioactivity normalized by injected dose (bottom)

[0103] Each row corresponds to a subject, and the columns correspond to the normalized IgG* dose in serum (i.e., [IgG*]*Vc IgG / dose), total radioactivity (i.e., [Vc IgG*

[0104] [IgG*]+Vp IgG*[IgG*]p+Ve*([IgG*]e+[IgG*-FcRn]e)] / dose). Observations from radiolabeling studies (Example 2.2) are shown in black.

[0105] The dots are shown, and the solid lines are the results of simulations using the empirical Bayes model parameter estimates for each subject.

[0106] Fig.15 Model individual goodness of fit for M281PK and endogenous IgG normalized to baseline IgG levels

[0107] Each row corresponds to the mean data for each SAD and MAD experimental group, and each column corresponds to the mean data for M281 PK (also called [M281]) and endogenous

[0108] The ratio of IgG to its baseline value (also called [IgG] / [IgG]baseline). Observations from the M281 SAD and MAD studies (Example 2.3) are shown as black dots.

[0109] and the solid lines are simulation results using the empirical Bayes model parameter estimates for each study group.

[0110] Fig.16 Simulated median and minimum / maximum time profiles for 33 subjects receiving kovalizumab alone (in black) or kovalizumab with IVIg (in blue). All concentrations are in uM

[0111] Median (solid line) and minimum / maximum (dashed line) simulated time profiles for 33 subjects receiving kovalizumab alone (black line) or kovalizumab with IVIg (blue line);

[0112] Kovalizumab regimen: 1000 mg IV on day 1 for patients less than 100 kg and 1500 mg for patients greater than 100 kg, followed by 340 mg SC on days 2, 8, 15, and 22.

[0113] IVIg regimen: 400 mg / kg per day on days 1, 2, 3, 4, and 5

[0114] Each graph corresponds to a different output of the model, i.e. total Crova = [Ab1] + [Ab1Ag] + [AgAb1Ag], total C5 = [Ag] + [Ab1Ag] + 2 [AgAb1Ag], total IgG = [IgG], Crova free paratope = 2 [Ab1] + [Ab1Ag], free crova = [Ab1], free C5 = [Ag]. All concentrations are expressed in uM.

[0115] Fig.17 Sensitivity Analysis #1: Total [FcRn] concentration divided by a factor of 2. Simulated median and min / max time profiles for 33 subjects receiving kovalizumab alone (in black) or kovalizumab with IVIg (in blue). All concentrations are in uM

[0116] Median (solid line) and minimum / maximum (dashed line) simulated time profiles for 33 subjects receiving kovalizumab alone (black line) or kovalizumab with IVIg (blue line);

[0117] Kovalizumab regimen: 1000 mg IV on day 1 for patients less than 100 kg and 1500 mg for patients greater than 100 kg, followed by 340 mg SC on days 2, 8, 15, and 22.

[0118] IVIg regimen: 400 mg / kg per day on days 1, 2, 3, 4, and 5

[0119] Each graph corresponds to a different output of the model, i.e. total Crova = [Ab1] + [Ab1Ag] + [AgAb1Ag], total C5 = [Ag] + [Ab1Ag] + 2 [AgAb1Ag], total IgG = [IgG], Crova free paratope = 2 [Ab1] + [Ab1Ag], free crova = [Ab1], free C5 = [Ag]. All concentrations are expressed in uM.

[0120] Fig.18 Sensitivity Analysis #2: Ve multiplied by 10. Simulated median and min / max time profiles for 33 subjects receiving kovalizumab alone (in black) or kovalizumab with IVIg (in blue).

[0121] All concentrations are in uM

[0122] Median (solid line) and minimum / maximum (dashed line) simulated time profiles for 33 subjects receiving kovalizumab alone (black line) or kovalizumab with IVIg (blue line); kovalizumab regimen: 1000 mg IV on day 1 for patients less than 100 kg and 1500 mg for patients greater than 100 kg, followed by 340 mg SC on days 2, 8, 15, and 22.

[0123] IVIg regimen: 400 mg / kg per day on days 1, 2, 3, 4, and 5

[0124] Each graph corresponds to a different output of the model, i.e. total Crova = [Ab1] + [Ab1Ag] + [AgAb1Ag], total C5 = [Ag] + [Ab1Ag] + 2 [AgAb1Ag], total IgG = [IgG], Crova free paratope = 2 [Ab1] + [Ab1Ag], free crova = [Ab1], free C5 = [Ag]. All concentrations are expressed in uM.

[0125] Fig.19 Sensitivity Analysis #3: IgG baseline multiplied by 2. Simulated median and min / max time profiles for 33 subjects receiving kovalizumab alone (in black) or kovalizumab with IVIg (in blue). All concentrations are in uM

[0126] Median (solid line) and minimum / maximum (dashed line) simulated time profiles for 33 subjects receiving kovalizumab alone (black line) or kovalizumab with IVIg (blue line);

[0127] Kovalizumab regimen: 1000 mg IV on day 1 for patients less than 100 kg and 1500 mg for patients greater than 100 kg, followed by 340 mg SC on days 2, 8, 15, and 22.

[0128] IVIg regimen: 400 mg / kg per day on days 1, 2, 3, 4, and 5

[0129] Each figure corresponds to a different output of the model, namely total Crova = [Ab1] + [Ab1Ag] + [AgAb1Ag], total C5 = [Ag] + [Ab1Ag] + 2 [AgAb1Ag], total IgG = [IgG], Crova free paratope = 2

[0130] [Ab1] + [Ab1Ag], free crova = [Ab1], free C5 = [Ag]. All concentrations are expressed in uM.

[0131] Fig. 20 Sensitivity Analysis #4: C5 baseline multiplied by 2. Simulated median and min / max time profiles for 33 subjects receiving kovalizumab alone (in black) or kovalizumab with IVIg (in blue).

[0132] All concentrations are in uM

[0133] Median (solid line) and minimum / maximum (dashed line) simulated time profiles for 33 subjects receiving kovalizumab alone (black line) or kovalizumab with IVIg (blue line);

[0134] Kovalizumab regimen: 1000 mg IV on day 1 for patients less than 100 kg and 1500 mg for patients greater than 100 kg, followed by 340 mg SC on days 2, 8, 15, and 22.

[0135] IVIg regimen: 400 mg / kg per day on days 1, 2, 3, 4, and 5

[0136] Each figure corresponds to a different output of the model, namely total Crova = [Ab1] + [Ab1Ag] + [AgAb1Ag], total C5 = [Ag] + [Ab1Ag] + 2 [AgAb1Ag], total IgG = [IgG], Crova free paratope = 2

[0137] [Ab1] + [Ab1Ag], free crova = [Ab1], free C5 = [Ag]. All concentrations are expressed in uM.

[0138] Fig.21Simulated median and minimum / maximum time profiles for 33 subjects receiving kovalizumab alone (in black) or kovalizumab with IVIg (in blue). All concentrations are in uM

[0139] Median (solid line) and minimum / maximum (dashed line) simulated time profiles for 33 subjects receiving kovalizumab alone (black line) or kovalizumab with IVIg (blue line);

[0140] Kovalizumab regimen: 1000 mg IV on day 1 for patients less than 100 kg and 1500 mg for patients greater than 100 kg, followed by 340 mg SC on days 2, 8, 15, and 22.

[0141] IVIg regimen: 400 mg / kg per day on days 1, 2, 3, 4, and 5

[0142] Each figure corresponds to a different output of the model, namely total Crova = [Ab1] + [Ab1Ag] + [AgAb1Ag], total C5 = [Ag] + [Ab1Ag] + 2 [AgAb1Ag], total IgG = [IgG], Crova free paratope = 2

[0143] [Ab1] + [Ab1Ag], free crova = [Ab1], free C5 = [Ag], Endo: free IgG = [IgG]e, Endo: free

[0144] Crova = [Ab1]e, Endo: Crova-FcRn = [Ab1-FcRn]e, Endo: Free IgG = [IgG]e, Endo: IgG-FcRn = [IgG-FcRn]e. All concentrations are expressed in uM.

[0145] Fig. 22 Simulated individual, median, and minimum / maximum time profiles for 33 subjects receiving kovalizumab alone. All concentrations are in uM

[0146] Individual (solid thick purple line), median (solid thick black line), and minimum / maximum (dashed lines) simulated time profiles for the 33 subjects who received kovalizumab alone;

[0147] Kovalizumab regimen: 1000 mg IV on day 1 for patients less than 100 kg and 1500 mg for patients greater than 100 kg, followed by 340 mg SC on days 2, 8, 15, and 22.

[0148] Each figure corresponds to a different output of the model, namely total Crova = [Ab1] + [Ab1Ag] + [AgAb1Ag], total C5 = [Ag] + [Ab1Ag] + 2 [AgAb1Ag], total IgG = [IgG], Crova free paratope = 2

[0149] [Ab1] + [Ab1Ag], free crova = [Ab1], free C5 = [Ag]. All concentrations are expressed in uM.

[0150] Fig.23 Simulated individual, median, and minimum / maximum time profiles for 33 subjects receiving kovalizumab and IVIg. All concentrations are in uM

[0151] Individual (solid thick purple line), median (solid thick black line), and minimum / maximum (dashed lines) simulated time profiles for 33 subjects receiving kovalizumab and IVIg;

[0152] Kovalizumab regimen: 1000 mg IV on day 1 for patients less than 100 kg and 1500 mg for patients greater than 100 kg, followed by 340 mg SC on days 2, 8, 15, and 22.

[0153] IVIg regimen: 400 mg / kg per day on days 1, 2, 3, 4, and 5

[0154] Each figure corresponds to a different output of the model, namely total Crova = [Ab1] + [Ab1Ag] + [AgAb1Ag], total C5 = [Ag] + [Ab1Ag] + 2 [AgAb1Ag], total IgG = [IgG], Crova free paratope = 2

[0155] [Ab1] + [Ab1Ag], free crova = [Ab1], free C5 = [Ag]. All concentrations are expressed in uM.

[0156] Examples

[0157] The following examples illustrate the present invention

[0158] Example 1: Antibodies and clinical trials

[0159] 1.1 Kovalimumab

[0160] The sequence of the anti-C5 antibody kovalimab is shown in SEQ ID NO: 1 (heavy chain) and SEQ ID NO: 2 (light chain). The generation of the anti-C5 antibody kovalimab used in the present invention is described in WO 2016 / 098356. In brief, the gene encoding the heavy chain variable domain (VH) (SEQ ID NO: 3) of 305LO15 is combined with the gene encoding the modified human IgG1 heavy chain constant domain (CH) variant SG115 (SEQ ID NO: 4). The gene encoding the light chain variable domain (VL) (SEQ ID NO: 5) of 305LO15 is combined with the gene encoding the human light chain constant domain (CL) (SK1, SEQ ID NO: 6). The antibody is expressed in HEK293 cells co-transfected with a combination of heavy chain and light chain expression vectors and purified by protein.

[0161] 1.2 Clinical trials

[0162] BN43118 is a phase III, randomized, double-blind, placebo-controlled, multicenter clinical study that will evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of kovalimab as an add-on therapy to the standard of care (SOC) for the treatment of patients with Guillain-Barré syndrome (GBS) compared to placebo. The study will recruit approximately 136 participants who will be randomized to double-blind treatment at a 1:1 ratio and receive kovalimab or placebo in addition to background therapy. In addition to SOC (IVIg), blinded study drugs (kovalimab or placebo) will be administered intravenously on day 1 and subcutaneously on days 2, 8, 15 and 22. Patients who have received background therapy before day 1 of the study must be able to receive the first dose of the blinded study drug before the last dose of background therapy. The study will consist of 4 phases: a 5-day screening period, a 4-week treatment period, and a 24-week follow-up after treatment.

[0163] Since the half-lives of IVIg and valimumab depend on recycling via the FcRn receptor in endosomes [9], a mathematical model was constructed to describe the effect of co-administration of IVIg on the PK of valimumab, taking into account the competition between the two molecules for binding to the FcRn receptor. This model is an extension of the valimumab PK / PD model describing the binding of valimumab to C5, which was developed for use in patients with untreated PNH and reported in

[10] , with the addition of competition for FcRn between IVIg and valimumab in endosomes. This report details the different components and assumptions of the model, as well as its calibration based on the valimumab COMPOSER clinical data

[11] and literature data on IVIg pharmacokinetic (PK). Simulations were performed to measure the effect of IVIg infusion on the PK / PD of valimumab and to assess whether complete C5 inhibition can be maintained over a 28-day period.

[0164] Example 2: Data used for modeling

[0165] To calibrate the combined IVIg PK and kovalimab PK / PD model, three sets of data were combined:

[0166] · PK / PD data from the COMPOSER clinical study of kovalizumab: Individual patient data were used to estimate the PK of kovalizumab and the binding parameters of kovalizumab to C5

[0167] IVIg PK data: Radiolabeled PK profiles of IVIg

[12] were used to estimate IVIg PK parameters in serum and endosomes

[0168] M281 PK / PD data: The PK time course of the monoclonal anti-FcRn antibody M281

[13] and its effect on endogenous IgG were used to estimate the volume of endosomal tissues and the concentration of FcRn receptors.

[0169] The COMPOSER data for kovalimab, the PK data for IVIg, and the PK / PD data for M281 are described in

[0170] In Example 2.1, Example 2.2 and Example 2.3, the values ​​of binding of Kovalimumab, IVIg and M281 to FcRn were required for model building and were fixed to their in vitro values ​​measured by surface plasmon resonance (SPR), as detailed in Example 2.4. Finally, the baseline value of IgG was fixed to represent the average level reported in the literature and described in Example 2.5.

[0171] The data checking and combining process is the same as that described in

[10] .

[0172] 2.1 COMPOSER Study BP39144

[0173] COMPOSER was a first-in-human study

[11] consisting of four sequential parts designed to evaluate the safety, tolerability, PK, and PD of kovalizumab in healthy volunteers (HV; Part 1), and in PNH patients who had not received eculizumab treatment (Parts 2 and 4) and in PNH patients who were switched from eculizumab to kovalizumab (Parts 3 and 4). Further details on the study design, the doses and schedules used, and the samples collected are given in

[10] .

[0174] This analysis included data from patients with HV and untreated PNH (not previously treated with eculizumab) available in the clinical database as of January 29, 2020. Of note, data from patients who switched from eculizumab to kovalizumab (Parts 3 and 4) were not used in this analysis because the GBS patients enrolled in the BN43118 study will be C5 inhibitor-naive

[10] . Using molecular weights of 190 kDa and 149 kDa for C5 and kovalizumab, respectively, concentrations of kovalizumab, total C5, and free C5 were converted to molar units (i.e., nM). The dose and administration rate were normalized by each subject's body weight at baseline and converted to molar units (i.e., the amount was in nmol / kg and the infusion rate for IV administration was in nmol / day / kg).

[0175] The number of samples available for analysis of total kovarizumab, free and total C5 in serum according to the COMPOSER assay is given in Table 1.

[0176] Table 1 Number of samples available for modeling with COMPOSER

[0177]

[0178] *: Only eculizumab-naïve patients from COMPOSER part 4 were included in the analysis

[0179] 2.2 Overview of IVIG PK Time Course

[0180] Figure 1 The six individual IVIg PK time profiles shown in Figure 1 were adapted from a study of radiolabeled IVIg by Kendrik et al.

[12] . The data for individual subjects consist of the time course of the proportion of the injected dose of IVIg remaining in serum and the time course of the proportion of the dose remaining in vivo. The health status of some individuals may result in different PK half-lives and increased or decreased serum IgG concentration levels. However, this analysis did not take into account the health status of the subjects.

[0181] 2.3 Overview of M281 PK / PD Time Course

[0182] To quantify the volume of endosomes and the number of available FcRn receptors in endosomes, data from the M281 monoclonal IgG1 anti-FcRn antibody

[13] , a high affinity FcRn binder (Kd = 28.7 pM at pH = 6.0), were used for model calibration. The mean PK profiles from the first-in-human (FIH) single ascending dose (SAD) study in healthy volunteers at doses of 3 mg / kg (n = 3), 10 mg / kg (n = 6), 30 mg / kg (n = 6), and 60 mg / kg (n = 6) were extracted from Figure 2(Reported in

[14] ). Since the PK profile of M281 in the MAD study is not available in the literature, only the SAD study provides the PK of IgG. Since M281 has a high affinity for FcRn at endosomal pH = 6.0, it will block the binding of endogenous IgG to FcRn and reduce serum IgG concentrations. Figure 3 Shown in SAD and MAD research along with the increase of M281 dosage the reduction of average serum endogenous IgG overview.These data provide the information about the average level of FcRn receptors that can be used for IgG recycling in endosome.For the SAD dosage of 3mg / kg (n=3), 10mg / kg (n=6), 30mg / kg (n=6) and 60mg / kg (n=5), and for the MAD dosage of 15mg / kg (n=3), 30mg / kg (n=3), average serum IgG concentration (in percentage relative to baseline) is extracted from this figure.

[0183] We note that even though the PK profile from the M281 MAD study was not available, the MAD time profile of IgG was used in the model calibration. Since individual subject data for M281 were not available, we assumed that

[0184] Each average profile for the different dose groups in the SAD and MAD studies corresponds to a different "individual" in the data set used for model calibration (and which includes individual data for kovalizumab and individual radiolabeled IgG PK profiles).

[0185] 2.4 Kovalizumab, IVIG and M281 FcRn binding

[0186] To model the interaction of kovalizumab, IgG and M281 with the FcRn receptor in endosomes, the in vitro association rate constants kon and dissociation rate constants koff between kovalizumab, IgG, M281 and FcRn were obtained from the literature and reported in Table 2.

[0187] Table 2 FcRn binding rate and constant at pH = 6.0

[0188] molecular kon(nM-1day-1) koff(Day -1) Kd(nM)=koff / kon Kovalimumab 1.35 230 170 IgG 1 100 100 M281 141 3.91 0.0287

[0189] Kd data for kovalizumab are from [7]; koff for kovalizumab is set to the IgG value reported in

[16] ; IgG data are from

[12] ; M281 data are from

[13] .

[0190] 2.5 IgG baseline concentration

[0191] Since endogenous baseline IgG concentrations were not available in any dataset, we assumed for model calibration and simulation that each patient had the same baseline IgG concentration. This concentration was fixed to 1 g / dL (i.e., 66.7 uM, assuming a molecular weight of IgG of 150e3 g / mol) as the normal IgG concentration range for adults has been reported to be between 0.767 g / dL and 1.59 g / dL

[17] .

[0192] Example 3: Modeling

[0193] 3.1 Methods

[0194] a) Model calibration strategy

[0195] A combined dataset consisting of the Kovalizumab COMPOSER data, IVIg PK data, and M281 PK / PD data (and described in Example 2) was used to simultaneously calibrate the Kovalizumab PK / PD, IVIg PK, and M281 PK / PD models. Population parameter estimates were obtained using a nonlinear mixed effects (NLME) approach, and individual parameter estimates were derived using empirical Bayesian estimation (EBE) as described in

[10] .

[0196] 3b) Software

[0197] Nonlinear mixed-effects analysis was performed using the Monolix software system version 2019R2 (Lixoft, Paris, France) to obtain parameter estimates. Simulations were performed using the R package mlxR version 4.1.5 in the R environment version 3.6.3.

[0198] c) Patient data inclusion criteria

[0199] All available subject / patient data from COMPOSER Parts 1, 2, and 4 described in Table 1 were included in this analysis.

[0200] d) Symbols

[0201] In the following part of the document, the close symbols defined in Table 3 are used to represent serum concentrations of kovalimab, C5, endogenous IgG or IVIg, radiolabeled IVIg, M281, and the complex formed by kovalimab binding to C5. Some of these amounts were also estimated in the peripheral compartment (with the suffix p) and endosomes (with the suffix e).

[0202] Table 3 Symbols used to describe free molecules and complexes in serum, peripheral compartments, and endosomes

[0203]

[0204]

[0205] 3.2. Model of Ab1, Ag, IVIg and M281 with FcRn recycling in endosomes

[0206] a) Model description

[0207] Figure 4 A model describing the binding of Ab1 (kovalizumab) to Ag(C5) and competition with IgG for FcRn recycling in endosomes is shown in FIG. It includes the following components:

[0208] Ab1 PK / PD model in serum: Figure 4 The upper part of contains two binding submodels, which describe the sequential binding process of one Ag protein to one arm of the free Ab1 antibody to form a complex Ab1Ag, followed by a second Ag protein binding to the second arm of the same antibody to form a complex AgAb1Ag (as described in

[10] ). The peripheral distribution compartment includes free and bound Ab1, where free Ab1 and the complex Ab1Ag and Ag Ab1Ag have two different distribution volumes. During the modeling process, it was observed that the data did not support the addition of Ag to the peripheral compartment. The ordinary differential equations (ODEs) describing the concentrations of free Ab1 (i.e. [Ab1]), free Ag (i.e. [Ag]), and Ab1 bound to one Ag (i.e. [Ab1Ag]) and two Ags (i.e. [AgAb1Ag]) are in Figure 5 Given in

[0209] IgG PK model in serum: Figure 4 The lower left part of the figure is a two-compartment linear disposition model for endogenous IgG or IVIg and radiolabeled IVIg (annotated with an asterisk, i.e., IgG*). The distribution volume and clearance of IgG and IgG* are assumed to be the same. Figure 6 The ODEs describing the concentrations of IgG and IgG* in serum are given in

[0210] M281 PK model in serum: A one-compartment linear disposition model was used to describe M281 PK. Figure 6 The ODE describing the concentration of M281 in serum is given in

[0211] Endosomal model: After internalization into endosomes, kovalimab, IgG, IgG*, and M281 antibodies can bind to FcRn and recycle back into the serum. Antibodies that do not bind to FcRn are eliminated from endosomes. ) We assumed that when the antibody is internalized into the endosome, Ag dissociates from the antibody complexes Ab1Ag and AgAb1Ag due to the thousand-fold increase in the dissociation constant KdAb1 (see [7]). Therefore, only free Ab1 exists in the endosome. Figure 7 An ODE describing binding to FcRn in endosomes is given in .

[0212] The definitions and descriptions of the model parameters are given in Table 4.

[0213] Table 4: Definition and units of model parameters

[0214]

[0215] The binding constants konAb1-Ag and koffAb1-Ag describe the binding of one arm of the Ab1 antibody to the Ag. Therefore, the probability that a free antibody with two free Fab arms available binds to free Ag is twice the probability that one arm of the antibody is already bound to an Ag. This is reflected in the model equation as Figure 5 2konAb1-Ag in the binding equation for free Ab1 in the medium. Similarly, the probability of an antibody that binds to two Ags losing an Ag molecule is twice the probability of the antibody binding to only one Ag. This is reflected in the equation describing the dissociation of two Ags bound to the antibody (i.e., AgAb1Ag), where the dissociation rate is twice, i.e. Figure 5 2koffAb1 in.

[0216] To describe the endosomal internalization and FcRn recycling of Ab1, the clearance term CLe,Ab1 was added to the ODE equation for Ab1 in serum with a minus sign, as Figure 8 As shown in Fig. 9 As shown in , the same term appears with a positive sign in the equation describing free Abl in endosomes (and after adjustment for the different distribution volumes between serum Vc and endosomal Ve). After binding to FcRn, Abl is recycled back to serum via the clearance term CLe, Abl recy, which is Fig. 9 In the endosome, it appears as a negative sign in the ODE equation of the Ab1-FcRn complex and Figure 8 Ab1 antibody that is not bound to FcRn in the endosome appears as a positive sign in the serum equation of Ab1. Fig. 9 Use the term ke,Ab1 to eliminate.

[0217] Similar parameters and equations were introduced into the model to describe the internalization and recycling of IgG, IgG*, and M281, as Figure 7 as shown in .

[0218] b) Summary of model assumptions

[0219] The main assumptions of the model are as follows:

[0220] If the second arm of Ab1 antibody is free or bound to another Ag protein, the binding rate of Ag to Ab1 (konAb1-Ag and koffAb1-Ag) is the same

[0221] Assuming that the in vitro surface plasmon resonance (SPR) estimate of this constant reflects the in vivo situation, koffAb1 was set to a fixed value for each subject

[0222] Ag binding to Ab1 occurs only in the central compartment (no binding in peripheral tissues)

[0223] The production rate (kinAg) and elimination rate (CLAg) of endogenous Ag remain unchanged over time.

[0224] Elimination into endosomes is linear and non-saturable

[0225] Only free Ab1 antibody was recycled (i.e. Ab1Ag and AgAb1Ag were recycled as Ab1) because we hypothesized that, in the endosome, due to the pH-dependent recycling technology SMART-Ig Ab1 does not bind to Ag

[0226] Assume that total [FcRn] concentration remains constant over time

[0227] The recycling process of FcRn from endosomes to serum is assumed to be linear and non-saturable (after binding to FcRn)

[0228] Since albumin binds to different FcRn epitopes than IgG, we believe that albumin does not participate in the FcRn recycling saturation process of IgG antibodies

[0229] Only free Ab1, IgG, IgG* and M281 are cleared from endosomes (i.e. all molecules bound to FcRn are recycled back to the serum)

[0230] We assume that the elimination constants of Ab1, IgG, IgG* and M281 in endosomes are the same, i.e., keAb1=keIgG=keM281

[0231] We hypothesized that removal of antibodies from the body occurs exclusively within endosomes.

[0232] Therefore, no consideration is given to the need to add other parallel processes that eliminate the constant

[0233] Example 4: Simulation and sensitivity analysis

[0234] 4.1 Basic case simulation

[0235] Patients receiving kovalizumab alone or co-administered with IVIg (both treatments started on the same day) were simulated using the following schedule:

[0236] Kovalizumab: 1000 mg IV on day 1 for patients less than 100 kg and 1500 mg for patients greater than 100 kg, followed by 340 mg SC on days 2, 8, 15, and 22

[0237] IVIg: 400 mg / kg daily on days 1, 2, 3, 4, and 5

[0238] • Simulations were performed using EBEs obtained from 33 subjects from the COMPOSER study included in the model calibration. EBEs from subjects from the radiolabeled IVIg and M281 studies were not used in the simulations because they do not contain any information on C5 inhibition.

[0239] For each subject, a baseline C5 concentration of 70 ug / mL and a baseline IgG concentration of 1 g / dL were assumed.

[0240] The main outputs of these simulations are median and minimum / maximum time-history profile values ​​for:

[0241] Total Ab1 drug concentration (in uM)

[0242] Total IgG concentration (in uM)

[0243] Free Ab1 (in uM)

[0244] Free Ab1 paratope concentration (in uM), i.e. the number of free Ab1 arms available for binding to Ag. This amount is given by the sum of 2x[Ab1]+[Ab1Ag]

[0245] In addition, the endosomal time course profiles of free FcRn, free IgG, free kovalizumab, and the complexes FcRn-kovalizumab, FcRn-IgG are provided in the Appendix.

[0246] The primary metrics used in the simulations comparing kovalizumab alone and kovalizumab with IVIg were the maximum decrease in median PK concentration at trough (at the time of kovalizumab administration) and the duration of complete C5 inhibition.

[0247] 4.2 Sensitivity analysis

[0248] To assess the robustness of the base case simulations, sensitivity analyses were performed to lower the threshold for FcRn recycling saturation under the following conditions:

[0249] The concentration of FcRn receptors in endosomes is divided by 2

[0250] The volume of the inner body multiplied by 10

[0251] Baseline IgG concentration multiplied by 2

[0252] In addition, because GBS is an acute disease, the individual differences in C5 levels are unclear; therefore, a simulation assuming an increase in baseline C5 concentration from 70 ug / mL to 140 ug / mL was performed in this sensitivity analysis.

[0253] All simulations were performed using the same dosing regimen, the same set of parameters representing the same 33 patients described in Example 4.1. In addition, the same metrics were used to compare sensitivity analyses with or without co-administration of IVIg.

[0254] Example 5: Results

[0255] 5.1 Modeling

[0256] This model (see Figure 4 ), describing the binding of Ag (i.e. C5) to Ab1 (i.e. variolizumab) and its competition with IgG in endosomes, calibrated using data from 15 healthy volunteers in COMPOSER Part 1, 10 and 8 untreated PNH patients from Parts 2 and 4, respectively, and the radiolabeled IgG* and M281 data described in Example 2. The available sample quantities of total Ab1, total Ag, free Ag from COMPOSER Parts 1, 2 and 4 are given in Table 1.

[0257] To reduce the uncertainty in the estimates due to the introduction of the endosomal part of the model, the population parameters of the central distribution volume, the volume and intercompartmental clearance of Ab1 and its complex with Ag, and the Ag production rate and clearance were fixed to the values ​​obtained without the endosomal model and described in

[10] . These values ​​are reported in Table 5.

[0258] Population parameter values ​​obtained from model calibration are reported in Table 6.

[0259] Fig.10 , Fig.11 , Fig.12 , Fig.13 The individual goodness-of-fit plots reported in show that the concentration time courses of total [Ab1], total [Ag], and free [Ag] from the COMPOSER study were adequately described by the model.

[0260] Fig.14The individual goodness-of-fit plots in show that the model adequately describes the dose-normalized radiolabeled IgG* in serum in the upper panel and the whole-body radioactivity in the lower panel.

[0261] Similarly, Fig.15 It was shown that M281 PK and its effects on baseline-normalized endogenous IgG concentrations were adequately described by the model for each arm of the SAD and MAD studies.

[0262] Table 5 Model population parameter estimates obtained from models without endosomes and reported in

[10] and fixed in the endosome model.

[0263]

[0264] The model parameters are defined in Table 4 , RSE = relative standard error of the estimate, CV = coefficient of variation, OFV = objective function value, AIC: Akaike information criterion, BIC: Bayesian information criterion, WT = body weight, a = additive error, b = proportional error SD.

[0265] The effect of WT on clearance was applied to the following parameters: CL Ag and Q Ab1

[0266] a Fixed value without random effects

[0267] Table 6 Model population parameter estimates

[0268]

[0269] Model parameters are defined in Table 4, RSE = relative standard error of the estimate, CV = coefficient of variation, OFV = objective function value, AIC: Akaike information criterion, BIC: Bayesian information criterion, WT = body weight, a = additive error, b = proportional error SD. The effect of WT on clearance was applied to the following parameters: CLe,Ab1, CLe,Ab1Ag, CLe,AgAb1Ag, CLe,IgG, CLe,M281, Q IgG, CLe,Ab1 recy, CLe,IgG recy, CLe,M281 rec

[0270] Example 6: Simulation and sensitivity analysis

[0271] 6.1 Basic case simulation

[0272] Simulations were performed using individual parameter estimates (ie, EBEs) from the 33 subjects in the COMPOSER study used in model calibration.

[0273] Simulation results for subjects who received kovalizumab alone or kovalizumab plus IVIg are shown in Fig.16 , where time 0 corresponds to day 1 of the start of treatment.

[0274] Appendix 1 Fig.21 Median and minimum / maximum simulated profiles of serum and endosome concentrations of kovalizumab and IgG are presented. The 33 individual profiles of subjects who received kovalizumab alone or kovalizumab and IVIg are depicted in Fig. 22 and Fig.23 middle.

[0275] When co-administered with the recommended dose of IVIg in GBS, decreased serum concentrations of kovalimab were observed due to its competition for FcRn recycling. In the presence of IVIg, median trough kovalimab concentrations decreased by 19% on day 8.

[0276] The median kovalizumab concentration over the simulation time remained above a threshold concentration of approximately 100 ug / mL, which is a value used as a reference for achieving complete C5 activity inhibition. Complete inhibition was confirmed when looking at the expected free C5 profile where complete inhibition was observed. In addition, the minimum value of the kovalizumab free paratope always remained above 0, indicating that there was always a kovalizumab binding reserve to capture free C5 molecules over the 72-day period.

[0277] 6.2 Sensitivity analysis

[0278] To assess the robustness of the assumptions made in the model, sensitivity analyses were performed on model parameters that affect FcRn recycling efficiency. In addition, since GBS is an acute disease and individual differences in C5 levels are unclear, simulations assuming an increase in baseline C5 concentrations were performed.

[0279] This analysis represents a potential “worst case scenario” with respect to reductions in C5 inhibition induced by changes in the PK of kovalizumab. The following model parameters were intentionally modified one by one, as follows:

[0280] 1. The total concentration of FcRn in the endosome [FcRn] is divided by a factor of 22. The endosomal volume Ve is multiplied by a factor of 10

[0281] 3. The production rate of endogenous IgG increases 2-fold, resulting in a doubling of the baseline concentration of IgG to a value of 2 g / dL

[0282] 4. The concentration of C5 at baseline increased by 2 times, from 70ug / mL to 140ug / mL

[0283] The results of sensitivity analysis No. 1 are shown in Fig.17The effect of IVIg on kovalizumab PK was higher when the concentration of FcRn in endosomes [FcRn] was always divided by a factor of 2; in this case, the median kovalizumab concentration was reduced by 27% at the trough value on day 8 in the presence of IVIg. Notably, this reduction was approximately 19% in the base case simulation. Over the 40-day period, the median profile remained above the 100 ug / ml threshold, and the minimum value of the kovalizumab free paratope remained strictly positive, ensuring complete C5 inhibition.

[0284] Fig.18 The results of sensitivity analysis No. 2 showed that a 10-fold increase in endosomal volume altered the PK profile of kovalizumab. However, no difference in the median kovalizumab concentration was observed with or without co-administration of IVIg.

[0285] In analysis No. 3, if Fig.19 As shown in , increasing the baseline endogenous level of IgG by 2-fold (from 1 g / dL to 2 g / dL) resulted in a 22% decrease in the median kovalizumab concentration on day 8; however, the values ​​of the kovalizumab free paratope remained strictly positive throughout the 40-day period. It is noteworthy that in the base case simulation, this decrease was approximately 19%.

[0286] Finally, in sensitivity analysis No. 4, simulations assuming a 2-fold increase in baseline C5 concentration (140 ug / mL) were performed and the results are presented in Fig. 20 The median trough concentration of kovalimab decreased by 22% on day 8.

[0287] These sensitivity analyses suggest that even when accounting for uncertainty regarding some key parameters driving FcRn recycling of kovalizumab, the proposed kovalizumab dosing strategy is expected to provide sufficient C5 inhibition for a period of at least 40 days based on the median PK profile.

[0288] Example 7 Discussion

[0289] The previously developed model for kovalizumab reported in

[10] was extended to account for saturation of FcRn recycling when IVIg is co-administered. A key assumption of this model is that antibody elimination occurs exclusively in endosomes when the antibody is not bound to FcRn (as is generally assumed in the literature [9]). Therefore, the half-life of the antibody depends on the extent to which the antibody can bind to FcRn receptors in the endosome and be recycled. Therefore, the concentration of FcRn receptors and the volume of endosomes are key parameters to be estimated to quantify when FcRn recycling will be saturated and will affect kovalizumab serum concentrations. The addition of the M281 PK / PD profile to our dataset provided the necessary information to estimate these two parameters, since binding of M281 to FcRn apparently saturates IgG recycling from endosomes to serum, as shown in Figure 2. Figure 3 We note that the population estimate of the concentration of FcRn receptors in endosomes reported in Table 6 [FcRn] total = 42.3 uM matches the reported value of 41.2 uM in Kendrik's publication

[12] (i.e. [FcRn] total = Rtot / v3 = 14umol / 0.34L). However, the estimated volume of endosomes Ve = 0.14L (assuming a body weight of 70kg) is 2.4 lower than the volume reported in the same publication (i.e. v3 = 0.34L), which prompted the use of M281 data to estimate this parameter.

[0290] After calibration, the model is Fig.14 PK and efficacy of IVIg in Fig.10 , Fig.11 , Fig.12 and Fig.13 The PK / PD of C5 inhibition by kovalimab shown in provides adequate goodness of fit. Fig.10 , Fig.11 , Fig.12 and Fig.13 As can be seen in the second column of , some of the variability in total [Ag] cannot be captured at the individual level. The model cannot capture the variability in total Ag because the model assumes that the rate of Ag production (i.e., kinAg) remains constant over time. For the 6 healthy volunteers who received placebo (i.e., subjects 11002, 11003, 11006, 11010, 11012, 11015), this is not true. Fig.10 and Fig.11 Specifically highlighted in FIG, these healthy volunteers had a constant predicted total Ag concentration (ie, the horizontal green line), while the measured total Ag varied over a 300 nM range.

[0291] At the population level, due to limited individual data for IgG and M281, the estimated precision of the parameters was generally poor (ie, RSE above 50%), as given in Table 6.

[0292] These findings justify why during the modeling process, the model parameters describing the PK / PD of kovalizumab and C5 in serum were fixed to the population values ​​given in Table 5 to reduce the estimated uncertainty about the parameters describing the FcRn recycling process. The values ​​in Table 5 were obtained using a model that does not explicitly describe the processes occurring in the endosome and are given in

[10] .

[0293] In order not to propagate uncertainty about population parameter estimates, only simulations using individual EBE parameters were performed. These EBEs were obtained for 33 subjects receiving kovalimab from the COMPOSER clinical study. EBE parameters obtained from subjects from radiolabeled IVIg and M281 studies were not used in the simulations because the parameters do not carry any information about kovalimab PK / PD.

[0294] Simulations indicated that the selected kovalizumab dosing regimen (1000 mg IV on day 1 for patients below 100 kg and 1500 mg for patients above 100 kg, followed by 340 mg SC on days 2, 8, 15, and 22) provided a median kovalizumab PK profile above the 100 ug / mL reference threshold (for complete C5 inhibition) when co-administered with IVIg at a dose of 400 mg / kg for 5 consecutive days. The maximum effect of IVIg co-administration occurred on day 8, with a 19% decrease in median serum kovalizumab concentrations. The levels of free paratopes remained strictly positive throughout the 72-day period, even taking into account the predicted minimum values ​​(which correspond to a small number of subjects), as can be seen in the Table 1. Fig.23 Observed in the individual profiles of .

[0295] Sensitivity analyses demonstrated the robustness of the results by assessing the impact of reducing FcRn receptor concentration by 2-fold, increasing endosomal volume by 10-fold, and increasing baseline IgG levels by 2-fold. In all of these cases, median serum concentrations of kovalizumab remained above 100 ug / mL over a 40-day period, and the minimum value of free paratope remained strictly positive over a 40-day period.

[0296] The increase in C5 baseline from 70 ug / mL to 140 ug / mL had a slight effect on median PK levels, as the decrease in median serum kovalizumab concentrations increased from 19% to 22% on Day 8. This increase was driven by the faster internalization rate of the kovalizumab-C5 complex compared to free kovalizumab (i.e., CLe,Ab1 = 0.00696 L / day / kg and CLe,Ab1Ag = CLe,AgAb1Ag = 0.0103 L / day / kg), which resulted in an overall faster elimination of kovalizumab.

[0297] Therefore, the selected kovalimab dosing regimen is expected to cover the treatment goal of maintaining sustained complete C5 inhibition for more than 28 days despite co-administration of IVIg.

[0298] Example 8 Summary / Conclusion

[0299] A mechanistic mathematical model was used to investigate the effects of IVIg infusion on the PK and PD profiles of kovalizumab in subjects receiving both treatments simultaneously. The PK / PD model describes the binding of kovalizumab to C5 and predicts the concentrations of free C5 and free kovalizumab paratopes over time (which quantifies the reserve of free kovalizumab sites available for binding to the C5 molecule).

[0300] The model also includes a PK model for endogenous IgG in serum and competition between IgG and kovalizumab for binding to FcRn receptors in endosomes. This part of the model allows for quantification of the effect of the recommended therapeutic dose of IVIg on kovalizumab PK concentrations. The model also includes a description of the PK and PD of the M281 anti-FcRn antibody used to estimate FcRn receptor concentrations and endosomal volume.

[0301] The PK / PD model of kovalimab, IVIg and M281 were simultaneously calibrated using a population approach. A combined dataset of kovalimab COMPOSER data from 33 healthy volunteers and untreated PNH patients, radiolabeled IgG data from six subjects from the literature

[12] , and published PK / PD SAD and MAD data of M281 monoclonal anti-FcRn antibody [13,14] was constructed and used for model calibration.

[0302] Simulations and sensitivity analyses were then performed using individual parameter estimates obtained from the 33 subjects in the COMPOSER clinical study to quantify the effect of IVIg co-administration on the PK and PD profiles of kovalizumab. These data were included in the calibration data set.

[0303] The following doses and dosing schedules of kovalimab and IVIg were used in these simulations:

[0304] Kovalizumab: 1000 mg IV on day 1 for patients less than 100 kg and 1500 mg for patients greater than 100 kg, followed by 340 mg SC on days 2, 8, 15, and 22

[0305] IVIg: 400 mg / kg daily on days 1, 2, 3, 4, and 5

[0306] The IVIg dose and administration schedule were based on standard treatment for acute GBS (400 mg / kg QD for 5 consecutive days).

[0307] The main conclusions of the modeling and simulation analysis are:

[0308] The predicted maximum reduction in median kovalizumab serum concentrations on Day 8 was 19% when concurrently receiving IVIg.

[0309] Median serum concentrations of kovalimab remained above approximately 100 ug / mL, the reference threshold expected to provide full C5 activity, for 72 days. This period encompasses the expected targeted treatment duration of the 28-day BN43118 study.

[0310] The level of free paratope remained strictly positive, indicating that there was always an available reserve of Kovalizumab binding.

[0311] Sensitivity analyses showed that complete C5 inhibition was maintained over the 40-day period even when model parameters such as FcRn receptor concentration, baseline levels of IgG and C5, and endosomal volume were changed in the direction of reducing FcRn recycling of kovalimab.

[0312] Overall, based on simulation results and sensitivity analyses, the selected dosing schedule of kovalimab could provide complete C5 inhibition for at least 40 days.

[0313] In conclusion, the proposed modeling approach provides a tool to understand the interaction of IVIg and kovalizumab on FcRn recycling and quantify the effect of IVIg on kovalizumab PK levels, kovalizumab free binding sites, and free C5 via simulations.

[0314] Based on the results of this study, the following dosing regimen was selected to be tested in clinical study BN43118

[0315] Kovalizumab: 1000 mg IV on day 1 for patients less than 100 kg and 1500 mg for patients greater than 100 kg, followed by 340 mg SC on days 2, 8, 15, and 22

[0316] However, to ensure that the selected dose is sufficient to achieve complete C5 inhibition, a dose confirmation step is planned for Study BN43118; actual PK data from 10 GBS subjects will be assessed to confirm the adequacy of the selected dose.

[0317] Abbreviations

[0318]

[0319]

[0320] sequence:

[0321]

[0322]

Claims

1. An anti-C5 antibody for use in a method for treating or preventing GBS in a subject, wherein the method The following steps are involved: a) intravenously administering a 1500 mg loading dose of the anti-C5 antibody once b) subsequently administering subcutaneously to said subject at least one 340 mg dose of said anti-C5 antibody.

2. The anti-C5 antibody for use according to claim 1, wherein a subcutaneous dose of 340 mg is administered to the subject at least once 1 day to 3 weeks after starting intravenous administration of the anti-C5 antibody.

3. The anti-C5 antibody for use according to claim 2, wherein IVIg is used in combination with the anti-C5 antibody for use in a method for treating or preventing GBS in a subject.

4. The anti-C5 antibody for use according to claim 3, wherein a dose of 400 mg / kg of IVIg is administered intravenously at least once.

5. The anti-C5 antibody for use according to claim 4, wherein the 400 mg / kg dose of IVIg is administered intravenously daily on days 1, 2, 3, 4 and 5. 6 . The anti-C5 antibody for use according to claims 2 to 5 , wherein a subcutaneous loading dose of 340 mg of the anti-C5 antibody is administered to the subject once 1 day after starting intravenous administration of the anti-C5 antibody.

7. The anti-C5 antibody for use according to claims 2 to 6, wherein at least one additional loading dose of 340 mg of the anti-C5 antibody is subcutaneously administered to the subject 1 week or 2 weeks after the start of intravenous administration of the anti-C5 antibody.

8. The anti-C5 antibody for use according to any one of claims 2 to 7, wherein an additional loading dose of 340 mg of the anti-C5 antibody is subcutaneously administered to the subject once a week 1 and 2 weeks after the start of intravenous administration of the anti-C5 antibody.

9. The anti-C5 antibody for use according to claim 6 or claim 7, wherein a dose of 340 mg of the anti-C5 antibody is subcutaneously administered to the subject several times repeatedly at intervals of at least 4 weeks.

10. The anti-C5 antibody for use according to any one of claims 1 to 9, wherein the method is performed by the following administration steps: (i) administering a 1500 mg loading dose of the anti-C5 antibody once intravenously to the subject; (ii) one day after starting intravenous administration of the anti-C5 antibody, subcutaneously administering a 340 mg dose of the anti-C5 antibody to the subject; (iii) administering a loading dose of 340 mg of the anti-C5 antibody subcutaneously to the subject once a week 1 week, 2 weeks, and 3 weeks after the start of intravenous administration of the anti-C5 antibody.

11. The anti-C5 antibody for use according to any one of claims 1 to 10, wherein the anti-C5 antibody is used in combination with IVIG, wherein the IVIg (a) 400 mg / kg of IVIg administered intravenously once on the same day as the loading dose of the C5 antibody in 1(i) (b) 400 mg / kg of IVIg was intravenously administered daily 1 day, 2 days, 3 days, and 4 days after the start of intravenous administration of the anti-C5 antibody.

12. An anti-C5 antibody for use according to any one of claims 1 to 11, wherein the subject has received previous treatment with at least one pharmaceutical product useful for treating or preventing a C5-related disease, wherein after the last dose of the pharmaceutical product, a 1500 mg intravenously administered loading dose of the anti-C5 antibody is administered to the subject.

13. The anti-C5 antibody for use according to any one of claims 1 to 12, wherein the subject has a body weight of more than 100 kg.

14. The anti-C5 antibody for use according to any one of claims 1 to 13, wherein the anti-C5 antibody concentration determined in the biological sample of the subject is 100 μg / ml or higher. 15 . The anti-C5 antibody for use according to any one of claims 1 to 14 , wherein the anti-C5 antibody is kovalizumab.

16. A combination of an anti-C5 antibody and IVIg for use in a method of treating or preventing GBS in a subject, preferably a subject having a body weight of more than 100 kg, wherein the method comprises the following consecutive steps: (i) administering to the subject a loading dose of 1500 mg of the anti-C5 antibody once intravenously, and administering 400 mg / kg of IVIg once intravenously on the same day; (ii) one day after starting intravenous administration of the anti-C5 antibody, administering to the subject subcutaneously a maintenance dose of 340 mg of the anti-C5 antibody, and administering 400 mg / kg of IVIg intravenously on the same day; (iii) 400 mg / kg of IVIg was intravenously administered daily on days 2, 3, and 4 after the start of intravenous administration of the anti-C5 antibody. (IV) 1 week (7 days), 2 weeks (14 days), and 3 weeks (21 days) after the start of intravenous administration of the anti-C5 antibody, a maintenance dose of 340 mg of the anti-C5 antibody is subcutaneously administered to the subject once a week.